// App-Quantinova.ai

5038 : A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma

Researchers

Presenter

  • Ted A. Gooley

Principal Investigators

  • Kathy Lilleby

  • Damian J. Green

  • Nicholas Burwick

  • Christine Wallace

  • Theodore Kim

  • Kiarash Kojouri

  • Erin Nelli

  • William I. Bensinger

Medical Centers

  • Seattle Cancer Care Alliance, Seattle, WA

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Gastrointestinal bleeding

  • Urinary tract infections

  • Deep vein thrombosis

  • Hand foot syndrome

  • Pulmonary embolism

  • Venous thrombosis

  • Multiple Myeloma

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Doxorubicin

  • Bortezomib

  • Warfarin

  • Aspirin

  • Albyl-E

  • Heparin

  • Doxorubicin Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00849251

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved